您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Carboplatin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Carboplatin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Carboplatin图片
CAS NO:41575-94-4
规格:98%
分子量:371.25
包装与价格:
包装价格(元)
100mg电议
200mg电议
500mg电议

产品介绍
Antitumor agent that forms platinum-DNA adducts.
CAS:41575-94-4
分子式:C6H12N2O4Pt
分子量:371.25
纯度:98%
存储:Store at -20°C

Background:

Carboplatin is a DNA synthesis inhibitor.


DNA synthesis is the natural or artificial creation of deoxyribonucleic acid (DNA) molecules.


Carboplatin inhibits DNA synthesis by binding to DNA and interfering with repair mechanism. In MTT assays with A2780, SKOV-3, IGROV-1 and HX62 human ovarian cancer cells, Carboplatin inhibited cell proliferation with IC50 of 6.2 μM, 12.4 μM, 2.2 μM and 116 μM for A2780, SKOV-3, IGROV-1 and HX62, respectively [1]. In UMC-11, H727 and H835 lung carcinoid cell line, Carboplatin also shows the anti-proliferative activities [2].


In xenograft-bearing mice, Carboplatin (60 mg/kg) had a modest antitumor effect and the relative tumor volumes on day 6 were 8.4 relative to the control of 11.9 [1]. Treatment of 56 small cell lung carcinoma patients with Carboplatin (300-400 mg/m2), 23 patients achieved a response including 5 complete remissions. 18 of 30 previously untreated patients achieved a response. Carboplatin was well tolerated and there was no nephrotoxicity [3].


参考文献:
[1].  Banerji U, Sain N, Sharp SY, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol, 2008, 62(5): 769-778.
[2].  Fiebiger W, Olszewski U, Ulsperger E, et al. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin Transl Oncol, 2011, 13(1): 43-49.
[3].  Smith IE, Evans BD. Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer. Cancer Treat Rev, 1985, 12 Suppl A: 73-75.